Formulation and investigation of 5-FU nanoparticles with factorial design-based studies.

This study describes an orthogonal experimental design to optimize the formulation of 5-fluorouracil (5-FU) loaded poly D,L (lactide-co-glycolide) (PLGA) nanoparticles (5FU-NP) by a nanoprecipitation-solvent displacement technique. The type of surfactant, amount of acetone and molecular weight of the polymer with three levels of each factor were selected and arranged in an L18(3(5)) orthogonal experimental table. From the statistical analysis of the data polynominal equations were generated. Optimized formulations have the particle size ranging from 160 to 250 nm. Smallest nanoparticles (161+/-1.22 nm) were obtained using Resomer PLGA 755 and pluronic F-68 with 10 ml acetone amount. Under these conditions the 5-FU entrapment percentage was maximum 78.30%, suggesting 5-FU might be entrapped and adsorbed on the nanoparticle surface. In vitro release of three formulations with maximum drug entrapment efficiency and minimum particle size, were also investigated by release kinetics. According to the determined coefficients, release data fit to Higuchi's diffusion kinetics. The in vitro release of 5FU-NP in phosphate buffered saline (PBS, pH 7.4) is suggested to be controlled by a combination of diffusion with slow and gradual erosion of the particles. Also, the antimicrobial activity was observed even on the end of seventh day with all formulations.

[1]  K. P. Rao,et al.  Release characteristics of bleomycin mitomycin C and 5-fluorouracil from gelatin microspheres , 1989 .

[2]  C Vigneron,et al.  Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[3]  E. Schacht,et al.  Polymeric prodrugs of 5-fluorouracil , 1997 .

[4]  M. Ercan,et al.  Microspheres of 5-fluorouracil using poly(dl-lactic acid): in vitro release properties and distribution in mice after i.v. administration , 1994 .

[5]  A. Florence,et al.  The Nature of the Oil Phase and the Release of Solutes from Multiple (w/o/w) Emulsions , 1986, The Journal of pharmacy and pharmacology.

[6]  Lisbeth Illum,et al.  Preparation of Biodegradable, Surface Engineered PLGA Nanospheres with Enhanced Lymphatic Drainage and Lymph Node Uptake , 1997, Pharmaceutical Research.

[7]  P. Couvreur,et al.  Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading , 1990 .

[8]  M. Hashida,et al.  Evaluation of water in oil and microsphere in oil emulsions as a specific delivery system of 5-fluorouracil into lymphatics. , 1977, Chemical & pharmaceutical bulletin.

[9]  A. Bozkır,et al.  Chitosan Nanoparticles for Plasmid DNA Delivery: Effect of Chitosan Molecular Structure on Formulation and Release Characteristics , 2004, Drug delivery.

[10]  O. Güven,et al.  In vitro and in vivo evaluation of PLAGA (50/50) microspheres containing 5-fluorouracil prepared by a solvent evaporation method , 1996 .

[11]  A. Florence,et al.  Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency , 1990, The Journal of pharmacy and pharmacology.

[12]  T. Fujita,et al.  Potential for lymphatic targeting of peptides , 1997 .

[13]  M. Morishita,et al.  Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. , 1999, Drug development and industrial pharmacy.

[14]  T. Gray,et al.  Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes , 1994, FEBS letters.

[15]  Hideyoshi Harashima,et al.  Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.

[16]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[17]  A. Coombes,et al.  The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery , 1993 .

[18]  Simon Benita,et al.  The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design , 1995 .

[19]  María J. Alonso,et al.  Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres , 1997 .

[20]  T. Saito,et al.  Selective delivery of pepleomycin to esophageal lymph nodes by activated carbon particles. , 1993, Anticancer research.

[21]  A. Hagiwara,et al.  Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases. , 1986, Anticancer research.

[22]  T. Park,et al.  Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release , 1999, Pharmaceutical Research.

[23]  M. Hashida,et al.  Studies on pharmaceutical modification of anticancer agents. II. Enhanced delivery of bleomycin into lymph by emulsions and drying emulsions. , 1975, Chemical & pharmaceutical bulletin.